PF-04958242

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SchizophreniaCognitive ImpairmentMemoryHearing Loss

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

1

Celexa

AbbVie

Preclinical

42

Ozempic

Novo Nordisk

Preclinical

13

Resotran

Takeda

Preclinical

14

Inapsine

Alnylam Pharmaceuticals

Preclinical

15

Zocor

OOrganon and Co

Preclinical

66

Depakote

AbbVie

Preclinical

—7

Ibrance

Pfizer

Preclinical

—8

Lunesta

Akero Therapeutics

Preclinical

39

Inversine

TTargacept Inc.

Preclinical

110

Catapres

Boehringer Ingelheim

Preclinical

1Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics2 trials

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Completed·Biogen·Phase 1·NCT01511510·39 enrolled

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

Completed·Biogen·Phase 1·NCT02341482·13 enrolled

Cognitive impairment2 trials

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Completed·Biogen·Phase 1·NCT01749098·29 enrolled

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Terminated·Biogen·Phase 2·NCT02855411·35 enrolled

Schizophrenia2 trials

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Completed·Biogen·Phase 1·NCT01518894·30 enrolled

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

Completed·Biogen·Phase 1·NCT02332798·39 enrolled

Single Dose1 trial

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Completed·Biogen·Phase 1·NCT02228395·12 enrolled

Memory1 trial

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

Completed·Biogen·Phase 1·NCT01365338·112 enrolled

4 more indications

Hearing Loss1 trial

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Completed·Biogen·Phase 1·NCT01518920·44 enrolled

Concentration1 trial

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

Completed·Biogen·Phase 1·NCT01646840·12 enrolled

Adult1 trial

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Terminated·Biogen·Phase 1·NCT01238679·20 enrolled

Unspecified1 trial

First-in-Human Study of PF-04958242 in Healthy Volunteers

Completed·Biogen·Phase 1·NCT01159483·24 enrolled

Details

Drug Info

Related News